Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- PMID: 24574716
- PMCID: PMC3923022
- DOI: 10.3748/wjg.v20.i2.475
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Abstract
It is estimated that 30% of the adult population in Japan is affected by nonalcoholic fatty liver disease (NAFLD). Fatty changes of the liver are generally diagnosed using imaging methods such as abdominal ultrasonography (US) and computed tomography (CT), but the sensitivity of these imaging techniques is low in cases of mild steatosis. Alanine aminotransferase levels may be normal in some of these patients, warranting the necessity to establish a set of parameters useful for detecting NAFLD, and the more severe form of the disease, nonalcoholic steatohepatitis (NASH). Although liver biopsy is currently the gold standard for diagnosing progressive NASH, it has many drawbacks, such as sampling error, cost, and risk of complications. Furthermore, it is not realistic to perform liver biopsies on all NAFLD patients. Diagnosis of NASH using various biomarkers, scoring systems and imaging methods, such as elastography, has recently been attempted. The NAFIC score, calculated from the levels of ferritin, fasting insulin, and type IV collagen 7S, is useful for the diagnosis of NASH, while the NAFLD fibrosis score and the FIB-4 index are useful for excluding NASH in cases of advanced fibrosis. This article reviews the limitations and merits of liver biopsy and noninvasive diagnostic tests in the diagnosis of NAFLD/NASH.
Keywords: Fibrosis; Liver biopsy; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Steatosis.
Figures
Similar articles
-
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004. Clin Liver Dis. 2018. PMID: 29128062 Review.
-
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.J Gastroenterol. 2011 Feb;46(2):257-68. doi: 10.1007/s00535-010-0305-6. Epub 2010 Sep 15. J Gastroenterol. 2011. PMID: 20842510
-
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18. Gastroenterology. 2019. PMID: 30660725 Free PMC article. Review.
-
Radiologic evaluation of nonalcoholic fatty liver disease.World J Gastroenterol. 2014 Jun 21;20(23):7392-402. doi: 10.3748/wjg.v20.i23.7392. World J Gastroenterol. 2014. PMID: 24966609 Free PMC article. Review.
-
The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.Clin Liver Dis. 2018 Feb;22(1):109-119. doi: 10.1016/j.cld.2017.08.006. Clin Liver Dis. 2018. PMID: 29128050 Review.
Cited by
-
Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.World J Hepatol. 2015 May 28;7(9):1192-208. doi: 10.4254/wjh.v7.i9.1192. World J Hepatol. 2015. PMID: 26019735 Free PMC article. Review.
-
Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease.Sci Rep. 2016 Jul 1;6:28814. doi: 10.1038/srep28814. Sci Rep. 2016. PMID: 27363523 Free PMC article.
-
Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease.Cureus. 2023 Oct 13;15(10):e46946. doi: 10.7759/cureus.46946. eCollection 2023 Oct. Cureus. 2023. PMID: 38021670 Free PMC article. Review.
-
Infrared spectral microscopy as a tool to monitor lung fibrosis development in a model system.Biomed Opt Express. 2020 Jun 25;11(7):3996-4007. doi: 10.1364/BOE.394730. eCollection 2020 Jul 1. Biomed Opt Express. 2020. PMID: 33014581 Free PMC article.
-
Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children.J Clin Cell Immunol. 2016 Feb;7(1):393. doi: 10.4172/2155-9899.1000393. Epub 2016 Feb 17. J Clin Cell Immunol. 2016. PMID: 27182456 Free PMC article.
References
-
- Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586–595. - PubMed
-
- Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649. - PubMed
-
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical